Article Details
Retrieved on: 2025-06-01 06:59:47
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the epidemiology of Lp(a) as a cardiovascular risk factor and evaluates therapeutic approaches like antisense oligonucleotides and small interfering RNAs, with trials for treatments such as pelacarsen, olpasiran, and lepodisiran, key for atherosclerosis and LDL management in cardiology.
Article found on: www.pharmacytimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here